<DOC>
	<DOCNO>NCT02158403</DOCNO>
	<brief_summary>The purpose study assess often blood clot form FDA-approved HeartMateÂ® II ( HM II ) Left Ventricular Assist Device ( LVAD ) identify risk related clot within pump .</brief_summary>
	<brief_title>PREVENtion HeartMate II Pump Thrombosis</brief_title>
	<detailed_description>PREVENT prospective , multi-center , non-randomized study design ( 1 ) ass incidence HM II pump thrombosis current era recommend practice clinical management adopt , ( 2 ) identify risk factor associate pump thrombosis event . The recommended practice focus implantation technique , anticoagulation regimen , pump speed blood pressure management . All consecutive patient receive HM II implant consider study .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>Subject legally authorize representative sign informed consent form Subject receive HeartMate II first Left Ventricular Assist Device ( LVAD ) Prior mechanical circulatory support ( MCS ) ( except intraaortic balloon pump ) Participation clinical investigation ( ) involve MCS device , investigation ( ) likely confound study result affect study outcome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HeartMate II</keyword>
	<keyword>heart assist device</keyword>
	<keyword>pump thrombosis</keyword>
	<keyword>hypercoagulable disorder</keyword>
	<keyword>thrombus</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>